Mirati Therapeutics

$184.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$4.10 (-2.17%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell MRTX and other stocks, options, and ETFs commission-free!

About MRTX

Mirati Therapeutics, Inc. Common Stock, also called Mirati Therapeutics, is a clinical-stage oncology company. Read More The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA. The listed name for MRTX is Mirati Therapeutics, Inc. Common Stock.

Employees
111
Headquarters
San Diego, California
Founded
1995
Market Cap
8.24B
Price-Earnings Ratio
Dividend Yield
Average Volume
371.27K
High Today
$193.49
Low Today
$182.72
Open Price
$191.92
Volume
460.63K
52 Week High
$203.77
52 Week Low
$66.01

Collections

MRTX Earnings

-$2.02
-$1.35
-$0.67
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 2, After Hours

You May Also Like